Synchrony 2022 Meeting Report: Catalyzing Research and Treatments

The paper summarizing our latest Synchrony Symposia was published in March 2023 edition of the Journal of Personalized Medicine. Synchrony 2022 brought together both basic and clinical sciences from both academia and industry to expedite the translation of autism research, not only from bench to bedside but also from the developmental stages in academia to commercialization in industry.

Physicians were able to take advantage of CME-accredited training to bring this knowledge to the fingertips of physicians who interact with patients every day.

This international conference provided a forum for world-renowned scientists and biotech and pharmaceutical companies to share their research on developing FDA-approved treatments for those who suffer from impairments caused by ASD and other developmental disabilities.

We thank the authors of this paper Heer Nanda and Richard Frye, and all the doctors and scientists who have contributed their time to make an impact on ASD research. For the pathways and the challenges of obtaining medications from the FDA-approved roundtable, we would like to thank Gabriel Belfort, M.D., Ph.D. (VP at Axial Therapeutics, Inc. Incorporation) for hosting the round table and the panelists: Gahan Pandina (Sr. Director Development at Janssen Inc.), John Slattery (CEO at BioROSA Technologies), Robert H. Ring (CEO at Kaerus Bioscience Ltd. Bio), Joanna Sambor (VP Regulatory Affairs at MapLight Therapeutics, Inc.), John Rodakis (Founder and President at N of One), and Kevin Sanders (Global Head of Neurodevelopment and Psychiatry at Genentech /Roche).

Nanda H, Frye RE. Synchrony 2022: Catalyzing Research and Treatments to Benefit Individuals with Neurodevelopmental Disorders including Autism Spectrum Disorders. Journal of Personalized Medicine. 2023; 13(3):490. doi.org/10.3390/jpm13030490

ABOUT SYNCHRONY
Synchrony Symposia brings together both basic and clinical sciences from both academia and industry to expedite the translation of autism research, not only from bench to bedside but also from the developmental stages in academia to commercialization in industry. Physicians are able to take advantage of CME-accredited training to bring this knowledge to the fingertips of physicians who interact with patients every day. This international conference provides a forum for world-renowned scientists and companies to share their research on developing FDA-approved treatments for autism and other developmental disabilities.